Stem cell transplants have shown promise in reversing the effects of stroke and restoring movement in mice, according to researchers at the University of Zurich. In their experiments, the treatment helped generate new neurons, restore movement, and initiate various forms of brain repair, marking a hopeful step toward regenerative therapies for neurological damage. Stroke is a widespread condition, affecting about one in four adults during their lifetime. Approximately half of those who experience a stroke are left with lasting issues, such as paralysis or difficulty speaking. These problems often occur when a stroke cuts off oxygen supply to parts of the brain or causes bleeding that destroys brain cells. Traditionally, such damage has been considered permanent, as there are currently no known treatments that can rebuild the affected brain tissue. The researchers used human neural stem cells, which have the ability to develop into different types of nervous system cells. These cells were derived from induced pluripotent stem cells, which are created by reprogramming ordinary human cells to regain the ability to become many different cell types. The team induced permanent strokes in mice, creating brain damage that closely mimics key aspects of human strokes. Since the transplanted cells were human, the mice were genetically modified to prevent their immune systems from rejecting the cells. One week after inducing the strokes, the researchers transplanted the neural stem cells directly into the damaged brain regions. They then monitored the effects using imaging techniques and biochemical analysis. The results showed that the treatment triggered a significant healing response. New blood vessels formed in the damaged brain tissue, inflammation decreased, and the blood-brain barrier— a protective barrier that separates the brain from the bloodstream—became more intact. Damage to this barrier can worsen inflammation and injury after a stroke. These biological changes were accompanied by improvements in the mice's movement. The stem cell treatment reversed the motor impairments caused by the strokes. Researchers measured these improvements, in part, using AI-assisted analysis of the animals' walking patterns. The researchers designed their experiments with eventual human treatment in mind. For example, the stem cells were produced without using reagents derived from animals. Avoiding animal-derived materials is crucial when developing therapies for human use, as it can reduce potential safety and regulatory issues. The University of Zurich team created a defined production protocol in collaboration with the Center for iPS Cell Research and Application (CiRA) at Kyoto University. Another key finding was the timing of the treatment: stem cell transplantation was more effective when performed one week after a stroke rather than immediately. This delay could make the therapy more practical in a clinical setting, giving doctors more time to prepare the treatment instead of delivering it during the immediate emergency period after a stroke. Despite the encouraging results, the researchers note that several challenges remain before the therapy can be tested widely in people. One concern is the risk of uncontrolled stem cell growth inside the brain. Tackenberg's group, working with Ruslan Rust, is developing a safety mechanism to prevent this. The team is also exploring a less invasive method of delivering the cells. Instead of transplanting them directly into brain tissue, they are developing an endovascular injection approach, where cells are delivered through blood vessels. This method could be more practical than traditional brain grafts. There is already a precedent for moving induced stem cell therapies into human testing, with initial clinical trials using induced stem cells to treat Parkinson's disease currently underway in Japan. According to Tackenberg, "Stroke could be one of the next diseases for which a clinical trial becomes possible."